[go: up one dir, main page]

PL2773360T3 - Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego - Google Patents

Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego

Info

Publication number
PL2773360T3
PL2773360T3 PL12844799T PL12844799T PL2773360T3 PL 2773360 T3 PL2773360 T3 PL 2773360T3 PL 12844799 T PL12844799 T PL 12844799T PL 12844799 T PL12844799 T PL 12844799T PL 2773360 T3 PL2773360 T3 PL 2773360T3
Authority
PL
Poland
Prior art keywords
nedd8
administration
enzyme inhibitor
activating enzyme
hypomethylating agent
Prior art date
Application number
PL12844799T
Other languages
English (en)
Inventor
Peter G. Smith
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Publication of PL2773360T3 publication Critical patent/PL2773360T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12844799T 2011-11-03 2012-11-02 Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego PL2773360T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555049P 2011-11-03 2011-11-03
EP12844799.2A EP2773360B1 (en) 2011-11-03 2012-11-02 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
PCT/US2012/063382 WO2013067396A2 (en) 2011-11-03 2012-11-02 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent

Publications (1)

Publication Number Publication Date
PL2773360T3 true PL2773360T3 (pl) 2018-09-28

Family

ID=48193039

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12844799T PL2773360T3 (pl) 2011-11-03 2012-11-02 Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego

Country Status (23)

Country Link
US (2) US8980850B2 (pl)
EP (1) EP2773360B1 (pl)
JP (2) JP6231988B2 (pl)
KR (1) KR101987861B1 (pl)
CN (1) CN104245699B (pl)
AU (1) AU2012321106C1 (pl)
BR (1) BR112014010699B1 (pl)
CA (1) CA2854461C (pl)
EA (1) EA028380B1 (pl)
ES (1) ES2668272T3 (pl)
GE (2) GEP20186940B (pl)
HK (1) HK1201733A1 (pl)
IL (1) IL232353B (pl)
MA (1) MA35662B1 (pl)
MX (1) MX357835B (pl)
MY (1) MY176125A (pl)
PH (1) PH12014501001B1 (pl)
PL (1) PL2773360T3 (pl)
SG (1) SG11201401895WA (pl)
TN (1) TN2014000194A1 (pl)
TR (1) TR201807342T4 (pl)
UA (1) UA114414C2 (pl)
WO (1) WO2013067396A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108986C2 (uk) 2009-05-14 2015-07-10 Мілленніум Фармасьютікалз, Інк. Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-[(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло[2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти)
US8809356B2 (en) * 2011-08-24 2014-08-19 Millennium Pharmaceuticals, Inc. Inhibitors of NEDD8-activating enzyme
EP2764866A1 (en) * 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
CA2923752A1 (en) 2013-05-14 2014-11-20 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
AU2014295019A1 (en) * 2013-07-26 2015-12-17 Boehringer Ingelheim International Gmbh Volasertib in combination with Azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome II
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
EP3362070B1 (en) * 2015-10-15 2021-01-27 Celgene Corporation Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia
WO2018218119A1 (en) * 2017-05-25 2018-11-29 The Board Of Trustees Of The Leland Stanford Junior University Combination of low dose il-2 and an inhibitor of treg il-2r desensitization to treat autoimmune and allergic inflammatory diseases
JP2020534331A (ja) * 2017-09-21 2020-11-26 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． （（１ｓ，２ｓ，４ｒ）−４−｛４−［（１ｓ）−２，３−ジヒドロ−１ｈ−インデン−１−イルアミノ］−７ｈ−ピロロ［２，３−ｄ］ピリミジン−７−イル｝−２−ヒドロキシシクロペンチル）メチルスルファメートの共結晶形態、その製剤及び使用
AU2019384547B2 (en) * 2018-11-20 2025-10-30 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
TWI845638B (zh) 2019-03-15 2024-06-21 美商弗爾康醫療公司 Ｅｅｄ及ｐｒｃ２調節劑之巨環唑并吡啶衍生物
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy
WO2023242235A1 (en) * 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
CN115007323B (zh) * 2022-06-17 2024-01-23 中南大学 一种抑制矿物中黄铁矿浮选的方法
WO2024012414A1 (en) * 2022-07-11 2024-01-18 Westlake University Use of a fbxo42 specific inhibitor in treating notch signaling-dependent disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7951810B2 (en) 2005-02-04 2011-05-31 Millennium Pharmaceuticals, Inc. Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes
DK1989206T3 (da) 2006-02-02 2012-10-08 Millennium Pharm Inc E1-aktiveringsenzymhæmmere
KR101555258B1 (ko) * 2006-08-08 2015-09-24 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ１ 활성화 효소의 억제제로서 유용한 헤테로아릴 화합물
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
WO2009058394A1 (en) 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
WO2009106549A2 (en) * 2008-02-26 2009-09-03 Nerviano Medical Sciences S.R.L. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
NZ589437A (en) 2008-05-15 2012-11-30 Celgene Corp Immediate release tablet comprising 5-azacytidine and a non-enteric coating applied with an ethanol solvent
ES2401951T3 (es) * 2008-06-09 2013-04-25 Cyclacel Limited Combinaciones de sapacitabina o CNDAC con inhibidores de ADN metiltransferasa tales como decitabina y procaína
ES2681529T3 (es) * 2009-03-23 2018-09-13 Ambit Biosciences Corporation Métodos de tratamiento utilizando terapia de combinación
UA108986C2 (uk) 2009-05-14 2015-07-10 Мілленніум Фармасьютікалз, Інк. Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-[(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло[2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти)
CA2825152A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
TWI558401B (zh) 2011-11-01 2016-11-21 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法

Also Published As

Publication number Publication date
WO2013067396A2 (en) 2013-05-10
TN2014000194A1 (en) 2015-09-30
GEAP201813483A (en) 2018-09-10
EP2773360A4 (en) 2015-09-23
IL232353A0 (en) 2014-06-30
IL232353B (en) 2018-11-29
JP6231988B2 (ja) 2017-11-15
HK1201733A1 (en) 2015-09-11
KR101987861B1 (ko) 2019-06-11
MA35662B1 (fr) 2014-11-01
GEP20186940B (en) 2019-01-10
MX357835B (es) 2018-07-26
JP2018009035A (ja) 2018-01-18
BR112014010699A2 (pt) 2017-04-25
SG11201401895WA (en) 2014-05-29
NZ624881A (en) 2016-10-28
AU2012321106B2 (en) 2016-08-04
GEP20196940B (en) 2019-01-10
BR112014010699B1 (pt) 2020-12-15
TR201807342T4 (tr) 2018-06-21
MX2014005323A (es) 2014-06-05
MY176125A (en) 2020-07-24
PH12014501001A1 (en) 2014-06-09
JP2015505816A (ja) 2015-02-26
US8980850B2 (en) 2015-03-17
EP2773360B1 (en) 2018-02-28
ES2668272T3 (es) 2018-05-17
PH12014501001B1 (en) 2018-05-04
CN104245699A (zh) 2014-12-24
CA2854461A1 (en) 2013-05-10
KR20140097229A (ko) 2014-08-06
US20150366886A1 (en) 2015-12-24
AU2012321106C1 (en) 2016-11-24
CA2854461C (en) 2021-01-19
EA028380B1 (ru) 2017-11-30
CN104245699B (zh) 2017-06-27
US20130116208A1 (en) 2013-05-09
WO2013067396A3 (en) 2014-10-16
EA201400539A1 (ru) 2014-12-30
AU2012321106A1 (en) 2013-05-23
UA114414C2 (uk) 2017-06-12
EP2773360A2 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
IL232353A0 (en) Administering an inhibitor of the 8nedd hemactab enzyme and a hypomethylated substance
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
ZA201401117B (en) Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof
EP2721019A4 (en) THERAPEUTIC ACTIVE COMPOSITIONS AND METHOD FOR THEIR USE
GB201411462D0 (en) Prebiotic formulations and methods of use
IL253911A0 (en) Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use
SG11201406948PA (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
EP2521551A4 (en) METHOD AND COMPOSITIONS FOR TARGETED ACTIVE DEVELOPMENT
ZA201206223B (en) Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof
ZA201400141B (en) Keto-isovalerate decarboxylase enzymes and methods of use thereof
EP2542074A4 (en) PHARMACEUTICAL COMBINATION ACTIVE AGENTS AS HCV REPLICATION INHIBITORS
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
IL230705A0 (en) Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
EP2790709A4 (en) HEMOSTATIC ACTIVE SUBSTANCES AND METHOD OF USE THEREOF
EP2563372A4 (en) PREBIOTIC FORMULATIONS AND METHODS OF USE
ZA201402820B (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
EP2714716A4 (en) MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS
EP2635287A4 (en) NEDD8 ACTIVATOR ENZYME INHIBITOR ADMINISTRATION
AP2014007413A0 (en) Stable dosage forms of arterolane and piperaquine
IL238406B (en) Mixed inhibitors of aminopeptidase n and nephrilysin
EP2996773A4 (en) Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
WO2012177684A9 (en) Use of caspase 3 activity and its inhibitors
HK1192727A (en) Combination of kanase inhibitors and uses thereof
AU2011903595A0 (en) Anti-thrombotic agent and methods of treatment
GB201112739D0 (en) Production and administration of therapeutic agents